Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Ann Dermatol Venereol ; 147(12): 853-856, 2020 Dec.
Article in French | MEDLINE | ID: mdl-33092890

ABSTRACT

INTRODUCTION: Sarcoidosis in patients of African or Afro-Caribbean origin presents semiological characteristics, together with polymorphic skin lesions, more extensive forms and a poorer prognosis. Ulcerated and particularly diffuse skin forms are very rare. Herein we report a case of diffuse ulcerated skin sarcoidosis appearing on top of old scars in a female patient of Afro-Caribbean origin. PATIENTS AND METHODS: A 16-year-old Caribbean girl consulted for multiple painful papules that appeared on old burns scars. The skin biopsy was consistent with sarcoidosis. At the same time, the patient developed sarcoid uveitis, and sarcoid dactylitis was suspected. Shortly thereafter, painful and diffuse ulcerations appeared on pre-existing skin lesions. Systemic corticosteroid therapy resulted in clinical improvement, but corticosteroid-dependency warranted subsequent initiation of methotrexate. DISCUSSION: Ulcerated cutaneous forms of sarcoidosis are rare and are often associated with severe forms, and they should prompt screening for systemic damage. There do not appear to be any previous reports of the presentation of ulcerated and extensive skin sarcoidosis presenting on scars, as described in the present study.


Subject(s)
Sarcoidosis , Skin Diseases , Adolescent , Adrenal Cortex Hormones/therapeutic use , Cicatrix/etiology , Female , Humans , Skin , Skin Diseases/chemically induced , Skin Diseases/drug therapy
3.
Am J Hematol ; 26(3): 279-84, 1987 Nov.
Article in English | MEDLINE | ID: mdl-3674007

ABSTRACT

Acquired pure red cell aplasia characterized by selective failure of erythropoiesis was seen in a 37-yr-old female patient with a diagnosis of chronic lymphatic leukemia (CLL). Though different immunosuppressive therapies have been tried in the past with variable response, there has been no case report of such favorable response to corticosteroids alone. We report this rare and unusual case of PRCA associated with CLL who responded to steroid therapy.


Subject(s)
Bone Marrow/pathology , Erythrocytes/cytology , Hematopoietic Stem Cells/cytology , Leukemia, Lymphoid/blood , Prednisone/therapeutic use , Adult , Blood Transfusion , Bone Marrow/drug effects , Erythrocytes/drug effects , Female , Hematopoietic Stem Cells/drug effects , Humans , Leukemia, Lymphoid/drug therapy , Leukemia, Lymphoid/therapy
4.
Contracept Fertil Sex (Paris) ; 13(10): 1063-7, 1985 Oct.
Article in French | MEDLINE | ID: mdl-12267711

ABSTRACT

PIP: Systemic lupus erythematosus usually affects young women of reproductive age and may be brought on or worsened by pregnancy or use of some oral contraceptives (OCs). At certain stages of the disease pregnancies are possible, but effective and reversible contraception permitting careful pregnancy planning is required. Amenorrhea is frequent in acute stages of the disease, but most authors have observed fertility levels in lupic women comparable to those of the population at large. Pregnancy complications and aggravations of lupus are much more rare when conception occurs during a stable remission of at least 6 months. Risks of lupus that must be considered in choosing a contraceptive method include vascular accidents such as venous thrombosis and inflammatory lesions of the arteries, hypertension usually secondary to nephropathy or corticotherapy, metabolic disturbances, anomalies of hemostasis, initiation or exacerbation of the disease with use of combined OCs, and predisposition to infection. Pills containing estrogen, even at low doses, are contraindicated because of the already high vascular risk of lupus patients and because estrogens may aggravate the condition. Progestins derived from 19 norsteroids are inadvisable because of the still imperfectly understood secondary effects which may include disturbances of metabolism or blood pressure. Low dose progestins or those derived from 17 hydroxyprogesterone appear to be a contraceptive of choice for lupus patients because of their lack of effects on metabolism or blood pressure. Their contraceptive efficacy is not quite as high as that of other OCs and they may entail a relative hyperestrogenic climate. They are not advisable in case of luteal insufficiency. IUDs are contraindicated because of the risk of infection, although they may be used in periods of remission for mild cases of lupus not treated with immunosuppressive drugs. Progestin-releasing IUDs may reduce risk of infection. Local methods have the advantage of being innocuous but their relatively high failure rate makes them inappropriate except for highly motivated women in stages of remission.^ieng


Subject(s)
Contraception , Lupus Erythematosus, Systemic , Women , Contraceptive Agents, Female , Contraceptives, Oral , Contraceptives, Oral, Hormonal , Disease , Family Planning Services , Intrauterine Devices , Intrauterine Devices, Medicated , Progesterone Congeners , Reproduction
SELECTION OF CITATIONS
SEARCH DETAIL
...